Ex vivo Generation of Platelets from Umbilical Cord Blood Hematopoietic Stem Cells with Amniotic Membrane Mesenchymal Stem Cells Support

Mardiah Suci Hardianti

doi:10.22146/acta interna.3845

Ex vivo Generation of Platelets from Umbilical Cord Blood Hematopoietic Stem Cells with Amniotic Membrane Mesenchymal Stem Cells Support

https://doi.org/10.22146/acta%20interna.3845

Mardiah Suci Hardianti^(1*)

(1)
(*) Corresponding Author

Abstract

ABSTRACT

Background: Platelet refractoriness is a major problem among patients requiring repeated transfusion. Production of less immunogenic platelets is required to overcome this problem. Umbilical cord blood (UCB) is rich in hematopoietic stem cells (HSC), which may serve as a potential source of less immunogenic ex vivo generated platelet. Development of methods to generate platelet from HSC in UCB with additions of various growth factors made a very high production cost. Amniotic membrane is widely known as the best source of mesenchymal stem cells (MSC), which may support the growth of platelet from HSC in UCB due to its abundant productions of cytokines and low cost .

Aim: This study aimed to generate platelet from UCB co-cultured with MSC derived from amniotic membrane.

Methods: Gradient density separation was performed to obtain mononuclear cells from UCB. The resulted mononuclear (MN) cells were selected for CD34+ by magnetic sorter beads. CD34+ HSC and non-CD34+ MN cells were each cultured in standard medium plus 10 ng/ml thrombopoietin (TPO), 50 ng/ml stem cell factor (SCF), and 25 ng/ml interleukin-11 (IL-11), with or without co-cultured with MSC. The MSC was also cultured alone with the addition of the above mentioned cytokines. Cultures were incubated in 37^o C with 5% CO2 and half of the medium was changed twice a week. Formations of platelets were confirmed by flowcytometry after two weeks culturing.

Results: Total number of CD34+ HSC was 1x10⁶, the non-CD34+ MNC was 1.78x10⁷and the MSC was 3x10⁵. Following the culture systems, the number of platelets produced from CD34+ HSC with and without MSC were 1.17% and 0.84%, respectively. The numbers of platelets produced from non-CD34+ MN cells with and without MSC were 7.94% and 8.85%, respectively. The number of platelets produced from 10⁵ MSC was 1.43%.

Conclusions: There was a greater increment in ex vivo production of platelets in CD34+ HSC isolated from UCB co-cultured with MSC, compared to that of without MSC. Further study to evaluate the significancy of the increament and the platelet function produced by this system is warranted.

Keywords: platelet, hematopoietic stem cells, - mesenchymal stem cells

Full Text:

ex vivo

References

Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH. Platelet transfusion for patients with cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-38.

British Society of Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.

Kon E, Filardo G, Delcogliano M, Lo Presti M, Russo A, Bondi A, Di Martino A, Cenacchi A, Fornasari PM, Marcacci M. Platelet-rich plasma: New clinical application. A pilot study of treatment of jumper’s knee. Injury, Int J Care Injured 2009; 40: 598-603.

Pallua N, Wolter T, Markowicz M. Platelet-rich plasma in burns. Burns 2009; DOI: 10.1016/j. burns. 2009.05.002.

Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: A review. Curr Rev Musculoskelet Med 2008; 1: 165-174.

World Health Organization. WHO’s Handbook of the Clinical Use of Blood. 2002. Geneva: WHO Blood Safety and Clinical Technology.

Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 2000; 14(2): 180-96.

Rebulla P. A mini-review on platelet refractoriness. Haematologica 2005; 90: 247-253.

Sacher RA, Kickler TS, Schiffer CA, Sherman LA, Bracey AW, Shulman IA. Management of patient’s refractory to platelet transfusion. Arch Pathol Lab Med 2003; 127: 409-14.

Kin DK, Fujiki T, Fukushima T, Ema H, Shibuya A, Nakauchi H. Comparison of hematopoietic activities of human bone marrow and umbilical cord blood CD34 positive and negative cells. Stem Cells 1999; 17: 286-94.

Wagner JE, Barker JN, DeFor TE, Baker S, Blazar BR, Eide C, Goldman A, Kersey J, Krivit W, MacMillan ML, Orchard PJ, Peters C, Weisdorf DJ, Ramsay NKC, Savies SM. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: Inﬂuence of CD34 cell dose and HLAdisparity on treatment-related mortality and survival. Blood 2002; 100: 1611-8.

Hwang WYK, Ong SY. Allogeneic haematopoietic stem cell transplantation without a matched sibling onor: Current options and future potential. Ann Acad Med Singapore 2009; 38: 340-5.

Matsunaga T, Tanaka I, Kobune M, Kawano Y, Tanaka M, Kuribayashi K, Iyama S, Sato T, Sato Y, Takimoto R, Takayama T, Kato J, Ninomiya T, Hamada H, Niitsu Y. Ex vivo large-scale generation of human platelets from cord blood CD34+ cells. Stem Cells 2006; 24: 2877-87.

Kang JW, Koo HC, Hwang SY, Kang SK, Ra JC, Lee MH, Park YH. Immunomodulatory effects of human amniotic membrane-derived mesenchymal stem cells. J Vet Sci. 2012 Mar; 13(1):23-31.

Marongiu F, Gramignoli R, Sun Q, Tahan V, Miki T, Dorko K, Ellis E, Strom SC. Isolation of amniotic mesenchymal stem cells. Curr Protoc Stem Cell Biol. 2010

Ungerer M, Peluso M, Gillitzer A, Massberg S, Heinzmann U, Schulz C, Munch G, Gawaz M. Generation of functional culture–derived platelets from CD34+ progenitor cells to study transgenic in the platelet environment. Circ Res 2004; 95: e36-e44.

Kratz-Albers K, Scheding S, Mohle R, Buhring HJ, Baum CM, Mc Kearn JP, Buchner T, Kanz L, Brugger W. Effective ex vivo generation of megakaryocytic cells of mobilized peripheral blood CD341 cells with stem cell factor and promegapoietin. Exp Hematol 2000; 28: 335-46.

Takayama N, Nishikii H, Usui J, Tsukui H, Sawaguchi A, Hiroyama T, Eto K, Nakauchi H. Generation of functional platelets of human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 2008; 111: 5298-306.

Le Blanc K and Ringden O. Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2005;11:321-334.

Magatti M, De Murani S, Vertua E, Gibelli L, Wengler GS, and Parolini O. Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells 2008; 26:182-192.

DOI: https://doi.org/10.22146/acta%20interna.3845